NABI BIOPHARMACEUTICALS : 25 Upcoming Catalysts :

Profil supprimé

03 juil. 2011 •07:43

http://www.biopharmcatalyst.com/news/25%20Upcoming%20Catalysts%20as%20of%20July% 202%202011/


25 Upcoming Catalysts as of July 2 2011:


Some short and long term potential catalysts as of July 2 2011 (share prices as at the close of trading Friday, July 1, 2011). See the links in the FDA Calendar for more details about each catalyst.

The possible catalysts listed below represent both short and long opportunities. It is NOT a recommendation to take SHORT or LONG positions in certain stock.

---------------------------------------------------


Antares Pharma, Inc. (AIS) $2.32 - PDUFA date December 8, 2011 for Anturol Gel in patients with overactive bladder (OAB).

Adolor Corporation (ADLR) $2.09 - Phase 2 data of ADL5945 in opioid-induced constipation (OIC) patients due 3Q 2011.

Alexza Pharmaceuticals, Inc. (ALXA) $1.81 - Resubmit NDA in July 2011 for AZ-004 (Staccato Loxapine) for agitation in schizophrenic or bipolar disorder patients.

ADVENTRX Pharmaceuticals, Inc. (ANX) $3.00 - PDUFA date of September 1, 2011 for Exelbine (ANX-530) for non-small cell lung cancer.

BioDelivery Sciences International, Inc. (BDSI) $3.27 - Phase 3 data of BEMA Buprenorphine for the treatment of chronic pain due 3Q 2011.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) $2.91 - Phase 3 efficacy data for LibiGel in patients with female sexual dysfunction (FSD) in October or November, 2011.

Celsion Corporation (CLSN) $3.13 - Pivotal Phase 3 ThermoDo clinical study (HEAT Study) for primary liver cancer. Interim analysis due September.

Depomed, Inc. (Nasdaq:DEPO) $8.39 - Phase 3 data BREEZE trial data evaluating Serada for menopausal hot flashes due 4Q.

Dynavax Technologies Corporation (DVAX) $2.72 - 12 month follow up data of Phase 3 HEPLISAV for HepB in comparison to Engerix due mid-July 2011.

Exelixis, Inc. (EXEL) $9.17 - Top-line data from Phase 3 trial of XL184 for medullary thyroid cancer (MTC) during mid-2011 and potentially file NDA during 2H 2011.

IntelGenx Corp. (OTCBB:IGXT) $0.83 - PDUFA date of November 13 for its antidepressant CPI-300.

Keryx Biopharmaceuticals (KERX) $4.89 - Phase 3 completion of KRX-0401 (perifosine) in patients with colorectal cancer during 2H 2011 (estimate 4Q rather than 3Q).

Lexicon Pharmaceuticals, Inc. (LXRX) $1.72 - Phase 2a data of LX 1032 for Carcinoid Syndrome due 3Q (estimate) 2011.

Nabi Biopharmaceuticals (NABI) $5.43 - Phase 3 Data of NicVAX for Nicotine Addiction due 2H - first of two Phase 3 trials.

NuPathe Inc. (PATH) $7.46 - PDUFA date of August 29, 2011 for Zelrix, a transdermal patch for the treatment of migraine.

Pacira Pharmaceuticals, Inc (PCRX) $12.03 - PDUFA date of November 28, 2011 for EXPAREL, a long-acting bupivacaine for postsurgical pain management.

Protalix BioTherapeutics Inc. (PLX) $6.31 - EMEA (European) Approval of Taliglucerase Alfa due possibly in 4Q 2011 based on 10mth timeline following validation. Note, no definitive dates for EMEA approval.

Repros Therapeutics Inc. (RPRX) $5.47 - Phase 2 interim analysis of Androxal in men with Type 2 Diabetes due September, 2011.

QLT Inc. (QLTI) $7.18 - Phase 2 data of latanoprost punctal plug drug delivery system (L-PPDS) in glaucoma. Data due 3Q 2011.

Raptor Pharmaceutical Corp (RPTP) $6.28 - Phase 3 data of cysteamine bitartrate in patients with nephropathic cystinosis due July 2011.

Repligen Corporation (RGEN) $3.60 - NDA filing, seeking priority review, of RG1068 for improvement of magnetic resonance imaging (MRI) of the pancreas due during summer of 2011.

Sangamo BioSciences, Inc. (SGMO) $5.96 - Phase 2b data of (SB-509-901) in subjects with diabetic neuropathy (DN) due 2H 2011.

Transcept Pharmaceuticals, Inc. (TSPT) $10.99 - PDUFA date of July 14, 2011 following Class 2 resubmission of Intermezzo for insomnia.

Vical Incorporated (Nasdaq:VICL) $4.11 - Phase 3 data of Allovectin-7 for melanoma due 2H 2011.

Zogenix, Inc. (ZGNX) $4.47 - Phase 3 data of ZX002 (Hydrocodone) for moderate to severe chronic pain in patients requiring around-the-clock opioid therapy due 3Q 2011.